Hydroxyurea

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans

Volumn 76, Issue , 2000, Pages 347-386

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA;

DRUG ANALYSIS; DRUG INDICATION; DRUG STRUCTURE; HUMAN; MOLECULAR WEIGHT; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; THROMBOCYTHEMIA;

EID: 0033909973     PISSN: 02509555     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (200)

1. Aliverti, V., Bonanomi, L. & Giavini, E. (1980) Hydroxyurea as a reference standard in teratological screening. Comparison of the embryotoxic and teratogenic effects following single intraperitoneal or repeated oral administrations to pregnant rats. Arch. Toxicol., Suppl. 4, 239-247
2. Amacher, D.E. & Turner, G.N. (1987) The mutagenicity of 5-azacytidine and other inhibitors of replicative DNA synthesis in the L5178Y mouse lymphoma cell. Mutat. Res., 176, 123-131
3. American Hospital Formulary Service (1997) AHFS Drug Information® 97, Bethesda, MD, American Society of Health-System Pharmacists, pp. 766-770
4. Andrae, U. (1984) Evidence for the involvement of cytochrome P-450-dependent monooxygenase(s) in the formation of genotoxic metabolites from N-hydroxyurea. Biochem. biophys. Res. Commun., 118, 409-415
5. Andrae, U. & Greim, H. (1979) Induction of DNA repair replication by hydroxyurea in human lymphoblastoid cells mediated by liver microsomes and NADPH. Biochem. biophys. Res. Commun., 87, 50-58
6. van den Anker-Lugtenburg, P.J. & Sizoo, W. (1990) Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea. Am. J. Hematol., 33, 152
7. Banga, S.S., Shenkar, R. & Boyd, J.B. (1986) Hypersensitivity of Drosophila mei-4I mutants to hydroxyurea is associated with reduced mitotic chromosome stability. Mutat. Res., 163, 157-165
8. Barbé, J., Villaverde, A. & Guerrero, R. (1987) Induction of the SOS response by hydroxyurea in Escherichia coli K12. Mutat. Res., 192, 105-108
9. Barr, M., Jr & Beaudoin, A.B. (1981) An exploration of the role of hydroxyurea injection time in fetal growth and terartogenesis in rats. Teratology, 24, 163-167
10. Beckloff, G.L., Lerner, H.J., Frost, D., Russo-Alesi, F.M. & Gitomer, S. (1965) Hydroxyurea in biologic fluids: Dose-concentration relationship. Cancer Chemother. Rep., 48, 57-58
11. Bellucci, S., Janvier, M., Tobelem, G., Flandrin, G., Charpak, Y., Berger, R. & Boiron, M. (1986) Essential thrombocythemias. Clinical evolutionary and biological data. Cancer, 58, 2440-2447
12. Belt, R.J., Haas, C.D., Kennedy, J. & Taylor, S. (1980) Studies of hydroxyurea administered by continuous infusion: Toxicity, pharmacokinetics, and cell synchronization. Cancer, 46, 455-462
13. Best, P.J.M. & Petitt, R.M. (1998) Multiple skin cancers associated with hydroxyurea therapy. Mayo Clin. Proc., 73, 961-963
14. Bhide, S.V. & Sirsat, M.V. (1973) Delayed effects of a single treatment of hydroxyurea to newborn mice. Indian J. Cancer, 10, 26-30
15. Biron, F., Lucht, F., Peyramond, D., Fresard, A., Vallet, T., Nugier, F., Grange, J., Malley, S., Hamedi-Sangsari, F. & Vila, J. (1996) Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals. Antiviral Res., 29, 111-113
16. Boyd, A.S. & Neldner, K.H. (1991) Hydroxyurea therapy. J. am. Acad. Dermatol., 25, 518-524
17. British Medical Association/Royal Pharmaceutical Society of Great Britain (1998) British National Formulary, No. 36, London, p. 377
18. British Pharmacopoeial Commission (1993) British Pharmacopoeia 1993, London, Her Majesty's Stationery Office, Vols I & II, pp. 343, 954, S68
19. Bruce, W.R. & Heddle, J.A. (1979) The mutagenic activity of 61 agents as determined by the micronucleus, Salmonella, and sperm abnormality assays. Can. J. Genet. Cytol., 21, 319-334
20. Brunner, R.L., McLean, M., Vorhees, C.V. & Butcher, R.E. (1978) A comparison of behavioral and anatomical measures of hydroxyurea induced abnormalities. Teratology, 18, 379-384
21. Budavari, S., ed. (1996) The Merck Index, 12th Ed., Whitehouse Station, NJ, Merck & Co., p. 833
22. Butcher, R.E., Scott, W.J., Kazmaier, K. & Ritter, E.J. (1973) Postnatal effects in rats of prenatal treatment with hydroxyurea. Teratology, 7, 161-165
23. van Buul, P.P. & Bootsma, A.L. (1994) The induction of chromosomal damage and cell killing in mouse spermatogonial stem cells following combined treatments with hydroxyurea, 3-aminobenzamide and X-rays. Mutat. Res., 311, 217-224
24. Callot-Mellot, C., Bodemer, C., Chosidow, O., Frances, C., Azgui, Z., Varet, B. & de Prost, Y. (1996) Cutaneous carcinoma during long-term hydroxyurea therapy: A report of 5 cases. Arch. Dermatol., 132, 1395-1397
25. Cattanach, B.M., Peters, J. & Rasberry, C. (1989) Induction of specific locus mutations in mouse spermatogonial stem cells by combined chemical X-ray treatments. Mutat. Res., 212, 91-101
26. Chan, P.C., Goldman, A. & Wynder, E.L. (1970) Hydroxyurea: Suppression of two-stage carcinogenesis in mouse skin. Science, 168, 130-132
27. Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B., Eckert, S.V., McMahon, R.P., Bonds, D.R. & the Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New Engl. J. Med., 332, 1317-1322
28. Charache, S., Barton, F.B., Moore, R.D., Terrin, M.L., Steinberg, M.H., Dover, G.J., Ballas, S.K., McMahon, R.P., Castro, O., Orringer, E.P. & the Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (1996) Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive 'switching' agent. Medicine, 75, 300-326
29. Chaube, S. & Murphy, M.L. (1966) The effects of hydroxyurea and related compounds on the rat fetus. Cancer Res., 26, 1448-1457
30. Chlopkiewicz, B. & Koziorowska, J.H. (1983) Transforming activities of methotrexate, hydroxyurea and 5-fluorouracil in different cell systems. Neoplasma, 30, 295-302
31. CIS Information Services (1998) Worldwide Bulk Drug Users Directory 1997/98 Edition, Dallas, TX [CD-ROM]
32. Cox, C., Nowicky, D. & Young, R. (1997) Hydroxyurea-related ankle ulcers in patients with myeloproliferative disorders: A case report and review of the literature. Ann. plast. Surg., 39, 546-549
33. Currie, J.L., Blessing, J.A., Muss, H.B., Fowler, J., Berman, M. & Burke, T.W. (1996a) Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: A Gynecologic Oncology Group study. Gynecol. Oncol., 61, 27-30
34. Currie, J.L., Blessing, J.A., McGehee, R., Soper, J.T. & Berman, M. (1996b) Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: A Gynecologic Oncology Group study. Gynecol. Oncol., 61, 94-96
35. Davidovitz, Y., Lev, D., Ballin, A., Tsudik, A. & Meytes, D. (1998) Short communication. Translocation (1;20)(q32;q13.3) in myelofibrosis following polycythemia vera. Cancer Genet. Cytogenet., 101, 156-158
36. De Boer, R.J., Boucher, C.A. & Perelson, A.S. (1998) Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS, 12, 1567-1570
37. De Haan, J.B. & Parker, M.I. (1988) Differential effects of DNA synthesis inhibitors on DNA methylation in normal and transformed cells. Anticancer Res., 8, 617-620
38. Delmer, A., Rio, B., Bauduer, F., Ajchenbaum, F., Marie, J.-P. & Zittoun, R. (1992) Pregnancy during myelosuppressive treatment for chronic myelogenous leukaemia (Letter to the Editor). Br. J. Haematol., 82, 783-784
39. DePass, L.R. & Weaver, E.V. (1982) Comparison of teratogenic effects of aspirin and hydroxyurea in the Fischer 344 and Wistar strains. J. Toxicol. environ. Health, 10, 297-305
40. DeSesso, J.M. (1981a) Comparative ultrastructural alterations in rabbit limb-buds after a teratogenic dose of either hydroxyurea or methotrexate. Teratology, 23, 197-215
41. DeSesso, J.M. (1981b) Amelioration of teratogenesis. I. Modification of hydroxyurea-induced teratogenesis by the antioxidant propyl gallate. Teratology, 24, 19-35
42. DeSesso, J.M. & Goeringer, G.C. (1990) The nature of the embryo-protective interaction of propyl gallate with hydroxyurea. Reprod. Toxicol., 4, 145-152
43. DeSesso, J.M. & Jordan, R.L. (1977) Drug-induced limb dysplasias in fetal rabbits. Teratology, 15, 199-211
44. DeSesso, J.M., Scialli, A.R. & Goeringer, G.C. (1994) D-Mannitol, a specific hydroxyl free radical scavenger, reduces the developmental toxicity of hydroxyurea in rabbits. Teratology; 49, 248-259
45. De Simone, C., Guerriero, C., Guidi, B., Rotoli, M., Venier, A. & Tartaglione, R. (1998) Multiple squamous cell carcinomas of the skin during long-term treatment with hydroxyurea. Eur. J. Dermatol., 8, 114-115
46. Diez-Martin, J.L., Graham, D.L., Petitt, R.M. & Dewald, G.W. (1991) Chromosome studies in 104 patients with polycythemia vera. Mayo Clin. Proc., 66, 287-299
47. Disdier, P., Harle, J.R., Grob, J.J., Weiller-Merli, C., Magalon, G. & Weiller, P.J. (1991) Rapid development of multiple squamous-cell carcinomas during chronic granulocytic leukemia. Dermatologica, 183, 47-48
48. Donehower, R.C. (1992) An overview of the clinical experience with hydroxyurea. Semin. Oncol., 19 (Suppl. 9), 11-19
49. Doney, K.C., Kraemer, K.G. & Shepard, T.H. (1979) Combination chemotherapy for acute myelocytic leukemia during pregnancy: Three case reports. Cancer Treat. Rep., 63, 369-371
50. Donovan, P.B., Kaplan, M.E., Goldberg, J.D., Tatarsky, I., Najean, Y., Silberstein, E.B., Knospe, W.H., Laszlo, J., Mack, K., Berk, P.D. & Wasserman, L.R. (1984) Treatment of polycythemia vera with hydroxyurea. Am. J. Hematol., 17, 329-334
51. Editions du Vidal (1998) Dictionnaire Vidal 1998, 74th Ed., Paris, OVP, pp. 889-890
52. Epstein, S.S., Arnold, E., Andrea, J., Bass, W. & Bishop, Y. (1972) Detection of chemical mutagens by the dominant lethal assay in the mouse. Toxicol. appl. Pharmacol., 23, 288-325
53. Evenson, D.P. & Jost, L.K. (1993) Hydroxyurea exposure alters mouse testicular kinetics and sperm chromatin structure. Cell Prolif., 26, 147-159
54. Fenech, M., Rinaldi, J. & Surralles, J. (1994) The origin of micronuclei induced by cytosine arabinoside and its synergistic interaction with hydroxyurea in human lymphocytes. Mutagenesis, 9, 273-277
55. Ferguson, L.R. (1990) Mutagenic and recombinogenic consequences of DNA-repair inhibition during treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea in Saccharomyces cerevisiae. Mutat. Res., 241, 369-377
56. Ferguson, L.R. (1995) Mutagenic properties of anticancer drugs. In: Ponder, B.A.J. & Waring, M.J., eds, The Genetics of Cancer, Lancaster, Kluwer Academic Publisher, pp. 177-216
57. Ferguson, L.R. & Denny, W.A. (1995) Anticancer drugs: An underestimated risk or an under-utilised resource in mutagenesis. Mutat. Res., 331, 1-26
58. Ferguson, L.R. & Turner, P.M. (1988a) 'Petite' mutagenesis by anticancer drugs in Saccharomyces cerevisiae. Eur. J. Cancer clin. Oncol., 24, 591-596
59. Ferguson, L.R. & Turner, P.M. (1988b) Mitotic crossing-over by anticancer drugs in Saccharomyces cerevisiae strain D5. Mutat. Res., 204, 239-249
60. Ferm, V.H. (1966) Severe developmental malformations. Arch. Pathol., 81, 174-177
61. Ferster, A., Vermylen, C., Cornu, G., Buyse, M., Corazza, F., Devalck, C., Fondu, P., Toppet, M. & Sariban, E. (1996) Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial. Blood, 88, 1960-1964
62. Fibach, E., Burke, K.P., Schechter, A.N., Noguchi, C.T. & Rodgers, G.P. (1993) Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia. Blood, 81, 1630-1635
63. Fitzgerald, J.M. & McCann, S.R. (1993) The combination of hydroxyurea and leucapheresis in the treatment of chronic myeloid leukaemia in pregnancy. Clin. Lab. Haematol., 15, 63-65
64. Foli, A., Maserati, R., Minoli, L., Wainberg, M.A., Gallo, R.C., Lisziewicz, J. & Lori, F. (1998) Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine. AIDS, 12, 1113-1114
65. Furgerson, J.L., Vukelja, S.J., Baker, W.J. & O'Rourke, T.J. (1996) Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. Am. J. Hematol., 51, 137-140
66. Galli, A. & Schiestl, R.H. (1996) Hydroxyurea induces recombination in dividing but not in G1 or G2 cell cycle arrested yeast cells. Mutat. Res., 354, 69-75
67. Gandhi, V., Plunkett, W., Kantarjian, H., Talpaz, M., Robertson, L.E. & O'Brien, S. (1998) Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. J. clin. Oncol., 16, 2321-2331
68. Gao, W. Y., Zhou, B.S., Johns, D.G., Mitsuya, H. & Yen, Y. (1998) Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2′,3′-dideoxyinosine. Biochem. Pharmacol., 56, 105-112
69. Gennaro, A.R. (1995) Remington: The Science and Practice of Pharmacy, 19th Ed., Easton, PA, Mack Publishing Co., Vol. II, p. 1252
70. Graham, P.J. (1955) Synthesis of Ureas. US Patent No. 2,705,727. Assigned to E.I. du Pont de Nemours & Co., Wilmington, DE
71. Greenwood, S.K., Armstrong, M.J., Hill, R.B., Bradt, C.I., Johnson, T.E., Hilliard, C.A. & Galloway, S.M. (1998) Fewer chromosome aberrations and earlier apoptosis induced by DNA synthesis inhibitors, a topoisomerase II inhibitor or alkylating agents in human cells with normal compared with mutant p53. Mutat. Res., 401, 39-53
72. Gropper, C.A., Don, P.C. & Sadjadi, M.M. (1993) Nail and skin hyperpigmentation associated with hydroxyurea therapy for polycythemia vera. Int. J. Dermatol., 32, 731-733
73. Guilhot, F., Abgrall, J.-F., Harousseau, J.-L., Bauters, F., Brice, P., Dine, G., Tilly, H., Ifrah, N., Cassasus, P., Rochant, H., Christian, B., Guerci, A., Lamagnere, J.-P., Le Prise, P.-Y., Duclos, B. & Tanzer, J. (1993) A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): Preliminary cytogenetic results. Leuk. Lymphoma, 11 (Suppl. 1), 181-183
74. Gwilt, P.R. & Tracewell, W.G. (1998) Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin. Pharmacokinet., 34, 347-358
75. Hahn, P., Kapp, L.N., Morgan, W.F. & Painter, R.B. (1986) Chromosomal changes without DNA overproduction in hydroxyurea-treated mammalian cells: Implications for gene amplification. Cancer Res., 46, 4607-4612
76. Hansen, D.K., Grafton, T.F., Cross, D.R. & James, S.J. (1995) Partial attenuation of hydroxyurea-induced embryotoxicity by deoxyribonucleotides in mouse and rat embryos treated in vitro. Toxicol. in Vitro, 9, 11-19
77. Hart, J.W. & Hartley-Asp, B. (1983) Induction of micronuclei in the mouse. Revised timing of the final stage of erythropoiesis. Mutat. Res., 120, 127-132
78. Haworth, S., Lawlor, T., Mortelmans, K., Speck, W. & Zeiger, E. (1983) Salmonella mutagenicity test results for 250 chemicals. Environ. Mutag., 5 (Suppl. 1), 3-142
79. Herken, R. (1984) The influence of deoxycytidine monophosphate (dCMP) on the cytotoxicity of hydroxyurea in the embryonic spinal cord of the mouse. Teratology, 30, 83-90
80. Herken, R. (1985) Ultrastructural changes in the neural tube of 10-day-old mouse embryos exposed to colchicine and hydroxyurea. Teratology, 31, 345-352
81. Hill, A.B. & Schimke, R.T. (1985) Increased gene amplification in L5178Y mouse lymphoma cells with hydroxyurea-induced chromosomal aberrations. Cancer Res., 45, 5050-5057
82. Holcombe, R.F., Treseler, P.A. & Rosenthal, D.S. (1991) Chronic myelomonocytic leukemia transformation in polycythemia vera. Leukemia, 5, 606-610
83. Ishii, Y. & Bender, M.A. (1980) Effects of inhibitors of DNA synthesis on spontaneous and ultraviolet light-induced sister-chromatid exchanges in Chinese hamster cells. Mutat. Res., 79, 19-32
84. Iversen, O.H. (1982a) Enhancement of methylnitrosourea skin carcinogenesis by inhibiting cell proliferation with hydroxyurea or skin extracts. Carcinogenesis, 3, 881-889
85. Iversen, O.H. (1982b) Hydroxyurea enhances methylnitrosourea skin carcinogenesis when given shortly before, but not after, the carcinogen. Carcinogenesis, 3, 891-894
86. Iwama, M., Sakamoto, Y., Honda, A. & Mori, Y. (1983) Limb deformity induced in chick embryo by hydroxyurea. J. Pharmacobiodyn., 6, 836-843
87. Jackson, H., Shukri, A. & Ali, K. (1993) Hydroxyurea treatment for chronic myeloid leukaemia during pregnancy. Br. J. Haematol., 85, 203-204
88. Jackson, M.A., Stack, H.F. & Waters, M.D. (1996) Genetic activity profiles of anticancer drugs. Mutat. Res., 355, 171-208
89. Jelmert, Ø., Hansteen, I.-L. & Langård, S. (1992) Enhanced cytogenetic detection of previous in vivo exposure to mutagens in human lymphocytes after treatment with inhibitors of DNA synthesis and DNA repair in vitro. Mutat. Res., 271, 289-298
90. Jiang, J., Jordan, S.J., Barr, D.P., Gunther, M.R., Maeda, H. & Mason, R.P. (1997) In vivo production of nitric oxide in rats after administration of hydroxyurea. Mol. Pharmacol., 52, 1081-1086
91. Johns, D.G. & Gao, W.Y. (1998) Selective depletion of DNA precursors: An evolving strategy for potentiation of dideoxynucleoside activity against immunodeficiency virus. Biochem. Pharmacol., 55, 1551-1556
92. Kaplan, M.E., Mack, K., Goldberg, J.D., Donovan, P.B., Berk, P.D. & Wassernan, L.R. (1986) Long-term management of polycythemia vera with hydroxyurea: A progress report. Semin. Hematol., 23, 167-171
93. Karon, M. & Benedict, W.F. (1972) Chromatid breakage: Differential effect of inhibitors of DNA synthesis during G2 phase. Science, 178, 62
94. Khera, K.S. (1979) A teratogenicity study on hydroxyurea and diphenylhydantoin in cats. Teratology, 20, 447-452
95. Kihlman, B.A. & Andersson, H.C. (1985) Synergistic enhancement of the frequency of chromatid aberrations in cultured human lymphocytes by combinations of inhibitors of DNA repair. Mutat. Res., 150, 313-325
96. Kunze, E., Graewe, T., Scherber, S., Weber, J. & Gellhar, P. (1989) Cell cycle dependence of N-methyl-N-nitrosourea-induced tumour development in the proliferating, partially resected urinary bladder. Br. J. exp. Pathol., 70, 125-142
97. Lambert, B., Sten, M., Söderhäll, S., Ringborg, U. & Lewensohn, R. (1983) DNA repair replication, DNA breaks and sister-chromatid exchange in human cells treated with adriamycin in vitro. Mutat. Res., 111, 171-184
98. Landaw, S.A. (1986) Acute leukemia in polycythemia vera. Semin. Hematol., 23, 156-165
99. Levin, V.A. & Prados, M.D. (1992) Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J. clin. Oncol., 10, 766-771
100. Li, J.C. & Kaminskas, E. (1987) Progressive formation of DNA lesions in cultured Ehrlich ascites tumor cells treated with hydroxyurea. Cancer Res., 47, 2755-2758
101. Liozon, E., Brigaudeau, C., Trimoreau, F., Desangles, F., Fermeaux, V., Praloran, V. & Bordessoule, D. (1997) Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. Hematol. Cell Ther., 39, 11-18
102. Lisziewicz, J., Jessen, H., Finzi, D., Siliciano, R.F. & Lori, F. (1998) HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor. Lancet, 352, 199-200
103. Löfvenberg, E. & Wahlin, A. (1988) Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur. J. Haematol., 41, 375-381
104. Löfvenberg, E., Nordenson, I. & Wahlin, A. (1990) Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease. Cancer Genet. Cytogenet., 49, 57-67
105. Lori, F., Gallo, R.C., Malykh, A., Cara, A., Romano, J., Markham, P. & Franchini, G. (1997a) Didanosine but not high doses of hydroxyurea rescue pigtail macaque from a lethal dose of SIV (smmpbj14). AIDS Res. hum. Retroviruses, 13, 1083-1088
106. Lori, F., Malykh, A.G., Foli, A., Maserati, R., De Antoni, A., Minoli, L., Padrini, D., Degli Antoni, A., Barchi, E., Jessen, H., Wainberg, M.A., Gallo, R.C. & Lisziewicz, J. (1997b) Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res. hum. Retroviruses, 13, 1403-1409
107. Loukopoulos, D., Voskaridou, E., Stamoulakatou, A., Papassotiriou, Y., Kalotychou, V., Loutradi, A., Cozma, G., Tsiarta, H. & Pavlides, N. (1998) Hydroxyurea therapy in thalassemia. Ann. N. Y. Acad. Sci., 850, 120-128
108. Luzzati, R., Di-Perri, G., Fendt, D., Ramarli, D., Broccali, G. & Concia, E. (1998) Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine (Letter). J. antimicrob. Chemother., 42, 565-566
109. Maier-Redelsperger, M., de Montalembert, M., Flahault, A., Neonato, M.G., Ducrocq, R., Masson, M.P., Girot, R. & Elion, J. for the French Study Group on Sickle Cell Disease (1998) Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. Blood, 91, 4472-4479
110. Mattano, S.S., Palella, T.D. & Mitchell, B.S. (1990) Mutations induced at the hypoxanthineguanine phosphoribosyltransferase locus of human T-lymphoblasts by perturbations of purine deoxyribonucleoside triphosphate pools. Cancer Res., 50, 4566-4571
111. Mayer, V.W., Goin, C.J. & Zimmermann, F.K. (1986) Aneuploidy and other genetic effects induced by hydroxyurea in Saccharomyces cerevisiae. Mutat. Res., 160, 19-26
112. Medical Economics Data Production (1999) PDR®: Physicians' Desk Reference, 53rd Ed., Montvale, NJ, Medical Economics
113. Mehnert, K., Vogel, W., Benz, R. & Speit, G. (1984) Different effects of mutagens on sister chromatid exchange induction in three Chinese hamster cell lines. Environ. Mutag., 6, 573-583
114. Millicovsky, G., DeSesso, J.M., Kleinman, L.I. & Clark, K.E. (1981) Effects of hydroxyurea on hemodynamics of pregnant rabbits: A maternally mediated mechanism of embryotoxicity. Am. J. Obstet. Gynecol., 140, 747-752
115. Minford, J., Kerrigan, D., Nichols, M., Shackney, S. & Zwelling, L.A. (1984) Enhancement of the DNA breakage and cytotoxic effects of intercalating agents by treatment with sublethal doses of 1-beta-D-arabinofuranosylcytosine or hydroxyurea in L1210 cells. Cancer Res., 44, 5583-5593
116. de Montalembert, M., Belloy, M., Bernaudin, F., Gouraud, F., Capdeville, R., Mardini, R., Philippe, N., Jais, J.P., Bardakdjian, J., Ducrocq, R., Maier-Redelsperger, M., Elion, J., Labie, D. & Girot, R. for the French Study Group on Sickle Cell Disease (1997) Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. J. pediatr. Hematol./Oncol., 19, 313-318
117. Montaner, J.S., Zala, C., Conway, B., Raboud, J., Patenaude, P., Rae, S., O'Shaughnessy, M.V. & Schechter, M.T. (1997) A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. J. infect. Dis., 175, 801-806
118. Moschella, S.L. & Greenwald, M.A. (1973) Psoriasis with hydroxyurea. An 18-month study of 60 patients. Arch. Dermatol., 107, 363-368
119. Muranyi-Kovacs, I. & Rudali, G. (1972) Comparative study of carcinogenic activity of hydroxyurea and urethane in XVII-G mice. Rev. Eur. Etud. clin. biol., 17, 93-95
120. Murphy, M.L. & Chaube, S. (1964) Preliminary survey of hydroxyurea (NSC-32065) as a teratogen. Cancer Chemother. Rep., 40, 1-7
121. Nair, R., Iyer, R.S., Nair, C.N., Kurkure, P.A., Pai, S.K., Saikia, T.K., Nadkarni, K.S., Pai, V.R., Gopal, R. & Advani, S.H. (1993) Myelodysplastic syndrome. A clinical and pathological analysis of 88 patients. Indian J. Cancer, 30, 169-175
122. Najean, Y. & Rain, J.-D. (1997a) Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood, 90, 3370-3377
123. 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood, 89, 2319-2327
124. 32P-or chemotherapy-treated patients with polycythemia vera: A prospective analysis of 682 cases. Leuk. Lymphoma, 22, 111-119
125. Nand, S., Messmore, H., Fisher, S.G., Bird, M.L., Schulz, W. & Fisher, R.I. (1990) Leukemic transformation in polycythemia vera: Analysis of risk factors. Am. J. Hematol., 34, 32-36
126. Nand, S., Stock, W., Godwin, J. & Fisher, S.G. (1996) Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am. J. Hematol., 52, 42-46
127. Navarra, P., Del Carmine, R., Ciabattoni, G., D'Amato, M., Ragazzoni, E., Vacca, M., Volpe, A.R. & Preziosi, P. (1990) Hydroxyurea: Relationship between toxicity and centrally-induced adrenal activation. Pharmacol. Toxicol, 67, 209-215
128. Navarra, P., Puccetti, P., Riccardi, C. & Preziosi, P. (1995) Anticancer drug toxicity via cytokine production: The hydroxyurea paradigm. Toxicol. Lett., 82-83, 167-171
129. Navarra, P., Tringali, G. & Preziosi, P. (1996) The effects of inhibitors of cyclo-oxygenase, lipoxygenase and nitric oxide synthase pathways on the toxicity of hydroxyurea in adrenalectomized rats. Toxicol. Lett., 86, 13-18
130. Navarra, P., Grohmann, U., Nocentini, G., Tringali, G., Puccetti, P., Riccardi, C. & Preziosi, P. (1997) Hydroxyurea induces the gene expression and synthesis of proinflammatory cytokines in vivo. J. Pharmacol. exp. Ther., 280, 477-482
131. Navarra, P., Tringali, G. & Preziosi, P. (1998) Hydroxyurea influences adrenocortical function in humans. Eur. J. clin. Pharmacol., 54, 491-492
132. Nyce, J., Liu, L. & Jones, P.A. (1986) Variable effects of DNA-synthesis inhibitors upon DNA methylation in mammalian cells. Nucleic Acids Res., 14, 4353-4367
133. Ören, H., Düzovali, O., Yüksel, E., Sakizli, M. & Irken, G. (1999) Development of acute promyelocytic leukemia with isochromosome 17q after BCR/ABL positive chronic myeloid leukemia. Cancer Genet. Cytogenet., 109, 141-143
134. Painter, R.B. & Cleaver, J.E. (1967) Radiobiology. Repair replication in HeLa cells after large doses of X-irradiation. Nature, 216, 369-370
135. Pajor, A., Zimonyi, I., Koos, R., Lehoczky, D. & Ambrus, C. (1991) Pregnancies and offspring in survivors of acute lymphoid leukemia and lymphoma. Eur. J. Obstet. Gynecol reprod. Biol., 40, 1-5
136. Palitti, F., Tanzarella, C., Degrassi, F., De Salvia, R., Fiore, M. & Natarajan, A.T. (1983) Formation of chromatid-type aberrations in G2 stage of the cell cycle. Mutat. Res., 110, 343-350
137. Palitti, F., Tanzarella, C., Degrassi, F., De Salvia, R. & Fiore, M. (1984a) Enhancement of induced sister chromatid exchange and chromosomal aberrations by inhibitors of DNA repair processes. Toxicol. Pathol., 12, 269-273
138. Palitti, F., Degrassi, F., De Salvia, R., Tanzarella, C. & Fiore, M. (1984b) Potentiation of induced sister chromatid exchanges and chromatid-type aberrations by inhibitors of DNA synthesis and repair in G2. Basic Life Sci., 29A, 313-318
139. Patel, M., Dukes, I.A.F. & Hull, J.D. (1991) Use of hydroxyurea in chronic myeloid leukemia during pregnancy: A case report. Am. J. Obstet. Gynecol., 165, 565-566
140. Philips, F.S. & Sternberg, S.S. (1975) Tests for tumour induction by antitumor agents. Recent Results Cancer Res., 52, 29-35
141. Popescu, N.C., Turnbull, D. & DiPaolo, J.A. (1977) Sister chromatid exchange and chromosome aberration analysis with the use of several carcinogens and noncarcinogens. J. natl Cancer Inst., 59, 289-293
142. Pouchert, C.J. (1981) The Aldrich Library of Infrared Spectra, 3rd Ed., Milwaukee, WI, Aldrich Chemical Co., p. 475
143. Pouchert, C.J. (1983) The Aldrich Library of NMR Spectra, 2nd Ed., Milwaukee, WI, Aldrich Chemical Co., Vol. 1, p. 671
144. Pouchert, C.J. (1985) The Aldrich Library of FT-IR Spectra, Milwaukee, WI, Aldrich Chemical Co., Vol. 1, p. 801
145. Prempree, T. & Merz, T. (1969) Does hydroxyurea inhibit chromosome repair in cultured human lymphocytes? Nature, 224, 603-604
146. Price, C.J., Tyl, R.W., Marks, T.A., Taschke, L.L., Ledoux, T.A. & Reel, J.R. (1985) Teratologic and postnatal evaluation of aniline hydrochloride in the Fischer 344 rat. Toxicol. appl. Pharmacol., 77, 465-478
147. Quesnel, B., Kantarjian, H., Pedersen Bjergaard, J., Brault, P., Estey, E., Lai, J.L., Tilly, H., Stoppa, A.M., Archimbaud, E., Harousseau, J.L., Bauters, F. & Fenaux, P. (1993) Therapy-related acute myeloid leukemia with t(8;21 ), inv(16), and t(8;16): A report on 25 cases and review of the literature. J. clin. Oncol., 11, 2370-2379
148. Reiffers, J., Dachary, D., David, B., Bernard, P., Marit, G., Boisseau, M. & Brousted, A. (1985) Megakaryoblastic transformation of primary thrombocythemia. Acta haematol., 73, 228-231
149. Richard, M., Truchetet, F., Friedel, J., Leclech, C. & Heid, E. (1989) Skin lesions simulating chronic dermatomyositis during long-term hydroxyurea therapy. J. Am. Acad. Dermatol., 21, 797-799
150. Rodriguez, G.I., Kuhn, J.G., Weiss, G.R., Hilsenbeck, S.G., Eckardt, J.R., Thurman, A., Rinaldi, D.A., Hodges, S., Von Hoff, D.D. & Rowinsky, E.K., (1998) A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood, 91, 1533-1541
151. Rossberger, S. & Andrae, U. (1985) DNA repair synthesis induced by N-hydroxyurea, acetohydroxamic acid, and N-hydroxyurethane in primary rat hepatocyte cultures: Comparative evaluation using the autoradiographic and the bromodeoxyuridine density-shift method. Mutat. Res., 145, 201-207
152. Rote Liste Sekretariat (1998) Rote Liste 1998, Frankfurt, Rote Liste Service GmbH, pp. 86-106, 86-115
153. Royal Pharmaceutical Society of Great Britain (1999) Martindale, The Extra Pharmacopoeia, 13th Ed., London, The Pharmaceutical Press [MicroMedex Online: Health Care Series]
154. Rutschmann, O.T., Opravil, M., Iten, A., Malinverni, R., Vernazza, P.L., Bucher, H.C., Bernasconi, E., Sudre, P., Leduc, D., Yerly, S., Perrin, L.H. & Hirschel, B. for the Swiss HIV Cohort Study (1998) A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. AIDS, 12, F71-F77
155. Sadtler Research Laboratories (1995) Sadtler Standard Spectra, 1981-1995 Supplementary Index, Philadelphia, PA, p. 1
156. Sato, K., Akaike, T., Sawa, T., Miyamoto, Y., Suga, M., Ando, M. & Maeda, H. (1997) Nitric oxide generation from hydroxyurea via copper-catalyzed peroxidation and implications for pharmacological actions of hydroxyurea. Jpn. J. Cancer Res., 88, 1199-1204
157. Schrell, U.M., Rittig, M.G., Anders, M., Koch, U.H., Marschalek, R., Kiesewetter, F. & Fahlbusch, R. (1997) Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J. Neurosurg., 86, 840-844
158. Scott, W.J., Ritter, E.J. & Wilson, J.G. (1971) DNA synthesis inhibition and cell death associated with hydroxyurea teratogenesis in rat embryos. Dev. Biol., 26, 306-315
159. Scott, J.P., Hillery, C.A., Brown, E.R., Misiewicz, V. & Labotka, R.J. (1996) Hydroxyurea therapy in children severely affected with sickle cell disease. J. Pediatr., 128, 820-828
160. Sharon, R., Tatarsky, I. & Ben-Arieh, Y. (1986) Treatment of polycythemia vera with hydroxyurea. Cancer, 57, 718-720
161. Simchen, G., Idar, D. & Kassir, Y. (1976) Recombination and hydroxyurea inhibition of DNA synthesis in yeast meiosis. Mol. Gen. Genet., 144, 21-27
162. Simonelli, C., Comar, M., Zanussi, S., De Paoli, P., Tirelli, U. & Giacca, M. (1997) No therapeutic advantage from didanosine (ddI) and hydroxyurea versus ddI alone in patients with HIV infection. AIDS, 11, 1299-1300
163. Skog, S., Heiden, T., Eriksson, S., Wallström, B. & Tribukait, B. (1992) Hydroxyurea-induced cell death in human T lymphoma cells as related to imbalance in DNA/protein cycle and deoxyribonucleotide pools and DNA strand breaks. Anticancer Drugs, 3, 379-386
164. Sofuni, T., Honma, M., Hayashi, M., Shimada, H., Tanaka, N., Wakuri, S., Awogi, T., Yamamoto, K.I, Nishi, Y. & Nakadate, M. (1996) Detection of in vitro clastogens and spindle poisons by the mouse lymphoma assay using the microwell method: Interim report of an international collaborative study. Mutagenesis, 11, 349-355
165. Stasi, R., Cantonetti, M., Abruzzese, E., Papi, M., Didona, B., Cavalieri, R. & Papa, G. (1992) Multiple skin tumors in long-term treatment with hydroxyurea (Letter to the Editor). Eur. J. Haematol., 48, 121-122
166. Stehman, F.B. (1992) Experience with hydroxyurea as a radiosensitizer in carcinoma of the cervix. Semin. Oncol., 19, 48-52
167. Stehman, F.B., Bundy, B.N., Kucera, P.R., Deppe, G., Reddy, S. & O'Connor, D.M. (1997) Hydroxyurea, 5-fluorouracil infusion, and cisplatin adjunct to radiation therapy in cervical carcinoma: A phase I-II trial of the Gynecologic Oncology Group. Gynecol. Oncol., 66, 262-267
168. Sterkers, Y., Preudhomme, C., Laï, J.-L., Demory, J.-L., Caulier, M.-T., Wattel, E., Borderssoule, D., Bauters, F. & Fenaux, P. (1998) Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion. Blood, 91, 616-622
169. Strauss, B., Coyle, M., McMahon, M., Kato, K. & Dolyniuk, M. (1972) DNA synthesis, repair and chromosome breaks in eucaryotic ceils. Johns Hopkins med. J., 1, 111-124
170. Swiss Pharmaceutical Society, ed. (1999) Index Nominum, International Drug Directory, 16th Ed., Stuttgart, Medpharm Scientific Publishers [MicroMedex Online: Health Care Series]
171. Sylvester, R.K., Lobell, M., Teresi, M.E., Brundage, D. & Dubowy, R. (1987) Excretion of hydroxyurea into milk. Cancer, 60, 2177-2178
172. Tanaka, M., Yamazaki, Y., Kondo, E., Hattori, M., Tsushita, K. & Utsumi, M. (1997) Achievement of a complete cytogenetic response with hydroxyurea in a patient with chronic myelogenous leukemia. Leuk. Res., 21, 465-468
173. Tefferi, A. (1998) Is hydroxyurea leukemagenic in essential thrombocythemia? (Letter to the Editor). Blood, 92, 1459-1460; discussion 1460-1461
174. Tertian, G., Tchernia, G., Papiernik, E. & Elefant, E. (1992)
175. Theisen, C.T., Fradkin, R. & Wilson, J.G. (1973) Teratogenicity of hydroxyurea in rhesus monkeys. Teratology, 7, A29
176. Thomas, J., ed. (1998) Australian Prescription Products Guide, 27th Ed., Victoria, Australian Pharmaceutical Publishing, Vol. 1, p. 1406
177. Timson, J. (1975) Hydroxyurea. Mutat. Res., 32, 115-132
178. Tohda, H. & Oikawa, A. (1990) Hypoxanthine enhances hydroxyurea-induced sister-chromatid exchanges in Chinese hamster ovary cells. Mutat. Res., 230, 235-240
179. Toraason, M., Bohrman, J.S., Krieg, E., Combes, R.D., Willington, S.E., Zajac, W. & Langenbach, R. (1992) Evaluation of the V79 cell metabolic co-operation assay as a screen in vitro for developmental toxicants. Toxicol. in Vitro, 6, 165-174
180. Triadou, P., Maier-Redelsperger, M., Krishnamoorty, R., Deschamps, A., Casadevall, N., Dunda, O., Ducrocq, R., Elion, J., Girot, R., Labie, D., Dover, G. & Cornu, P. (1994) Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. Nouv. Rev. Fr. Hematol., 36, 367-372
181. Tsutsui, T., Barrett, J.C. & Ts'o, P.O.P. (1979) Morphological transformation, DNA damage, and chromosomal aberrations induced by a direct DNA perturbation of synchronized Syrian hamster embryo cells. Cancer Res., 39, 2356-2365
182. US Pharmacopeial Convention (1994) The 1995 US Pharmacopeia, 23rd Rev./The National Formulary, 18th Rev., Rockville, MD, pp. 776-777
183. US Pharmacopeial Convention (1998) USP Dispensing Information, Vol. I, Drug Information for the Health Care Professional, 18th Ed., Rockville, MD, pp. 1607-1609
184. Van den Berg, C.L., McGill, J.R., Kuhn, J.G., Walsh, J.T., De La Cruz, P.S., Davidson, K.K., Wahl, G.M. & Von Hoff, D.D. (1994) Pharmacokinetics of hydroxyurea in nude mice. Anticancer Drugs, 5, 573-578
185. Velez, A., Lopez-Rubio, F. & Moreno, J.C. (1998) Chronic hydroxyurea-induced dermatomyositis-like eruption with severe dermal elastosis. Clin. exp. Dermatol., 23, 94-95
186. Vila, J., Nugier, F., Bargues, G., Vallet, T., Peyramond, D., Hamedi-Sangsari, F. & Seigneurin, J.M. (1997) Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet, 350, 635-636
187. Villani, P., Maserati, R., Regazzi, M.B., Giacchino, R. & Lori, F. (1996) Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. J. clin. Pharmacol., 36, 117-121
188. Vorhees, C.V., Butcher, R.E., Brunner, R.L. & Sobotka, T.J. (1979) A developmental test battery for neurobehavioral toxicity in rats: A preliminary analysis using monosodium glutamate calcium carrageenan, and hydroxyurea. Toxicol. appl. Pharmacol., 50, 267-282
189. Vorhees, C.V., Butcher, R.E., Brunner, R.L., Wootten, V. & Sobotka, T.J. (1983) Developmental toxicity of phychotoxicity of FD and C red dye No. 40 (allura red AC) in rats. Toxicology, 28, 207-217
190. Voskaridou, E., Kalotychou, V. & Loukopoulos, D. (1995) Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell/beta-thalassaemia. Br. J. Haematol., 89, 479-484
191. Wadler, S., Haynes, H., Schechner, R., Rozenblit, A. & Wiernik, P.H. (1996) Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-alpha-2a in patients with advanced malignancies. Invest. New Drugs, 13, 315-320
192. Wangenheim, J. & Bolcsfoldi, G. (1988) Mouse lymphoma L5178Y thymidine kinase locus assay of 50 compounds. Mutagenesis, 3, 193-205
193. Warner, C. W., Sadler, T. W., Shockey, J. & Smith, M.K. (1983) A comparison of the in vivo and in vitro response of mammalian embryos to a teratogenic insult. Toxicology, 28, 271-282
194. Weinfeld, A., Swolin, B. & Westin, J. (1994) Acute leukaemia after hydroxyurea therapy in polycythemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur. J. Haematol., 52, 134-139
195. Weinlich, G., Schuler, G., Greil, R., Kofler, H. & Fritsch, P. (1998) Leg ulcers associated with long-term hydroxyurea therapy. J. Am. Acad. Dermatol., 39, 372-374
196. West, W.O. (1987) Hydroxyurea in the treatment of polycythemia vera: A prospective study of 100 patients over a 20-year period. South. med. J., 80, 323-327
197. Wiger, R., Hongslo, J.K., Evenson, D.P., De Angelis, P., Schwartze, P.E. & Holme, J.A. (1995) Effects of acetaminophen and hydroxyurea on spermatogenesis and sperm chromatin structure in laboratory mice. Reprod. Toxicol., 9, 21-33
198. Wilson, J.G. (1974) Teratogenic causation in man and its evaluation in non-human primates. In: Motulsky, A.G. & Lenz, W., eds, Birth Defects. Proceedings of 4th International Conference, Amsterdam, Excerpta Medica, pp. 191-203
199. Wilson, J.G., Scott, W.J., Ritter, E.J. & Fradkin, R. (1975) Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys. Teratology, 11, 169-178
200. Zaborowska, D., Swietlinska, Z. & Zuk, J. (1983) Induction of mitotic recombination by UV and diepoxybutane and its enhancement by hydroxyurea in Saccharomyces cerevisiae. Mutat. Res., 120, 21-26